AstraZeneca and Takeda Partner on Development of Parkinson’s Candidate
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 9 (Table of Contents)
Published: 7 Sep-2017
DOI: 10.3833/pdr.v2017.i9.2273 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
AstraZeneca and Takeda have signed a deal potentially worth up to US$400 M to co-develop and co-commercialise AstraZeneca’s MEDI1341...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS